PDL BioPharma, Inc. (NASDAQ:PDLI) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Friday.
PDLI has been the subject of several other research reports. Zacks Investment Research upgraded PDL BioPharma from a “sell” rating to a “hold” rating in a report on Monday, May 15th. ValuEngine upgraded PDL BioPharma from a “hold” rating to a “buy” rating in a report on Friday, August 4th. Cowen and Company reiterated a “hold” rating on shares of PDL BioPharma in a report on Wednesday, May 3rd. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $4.00 price objective on shares of PDL BioPharma in a report on Thursday. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $3.50.
Shares of PDL BioPharma (NASDAQ PDLI) traded up 4.054% during midday trading on Friday, reaching $2.695. The company’s stock had a trading volume of 930,972 shares. The company’s 50-day moving average price is $2.43 and its 200 day moving average price is $2.28. The company has a market capitalization of $415.25 million, a P/E ratio of 6.195 and a beta of 0.58. PDL BioPharma has a 12-month low of $1.93 and a 12-month high of $3.77.
PDL BioPharma (NASDAQ:PDLI) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.17. PDL BioPharma had a return on equity of 9.07% and a net margin of 23.03%. The business had revenue of $143.80 million during the quarter, compared to analysts’ expectations of $56.30 million. During the same quarter last year, the business posted $0.09 EPS. The business’s revenue was up 584.8% on a year-over-year basis. On average, equities research analysts forecast that PDL BioPharma will post $0.47 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This article was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/2801842/pdl-biopharma-inc-pdli-rating-increased-to-hold-at-bidaskclub.html.
A number of large investors have recently added to or reduced their stakes in PDLI. FMR LLC boosted its stake in PDL BioPharma by 14.3% in the fourth quarter. FMR LLC now owns 934,050 shares of the biotechnology company’s stock valued at $1,980,000 after buying an additional 116,700 shares during the period. Dimensional Fund Advisors LP boosted its stake in PDL BioPharma by 15.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,282,180 shares of the biotechnology company’s stock valued at $9,078,000 after buying an additional 582,265 shares during the period. HPM Partners LLC acquired a new stake in PDL BioPharma during the first quarter valued at $163,000. Seizert Capital Partners LLC acquired a new stake in PDL BioPharma during the first quarter valued at $2,706,000. Finally, Norges Bank acquired a new stake in PDL BioPharma during the fourth quarter valued at $5,068,000. Institutional investors and hedge funds own 83.72% of the company’s stock.
About PDL BioPharma
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
Receive News & Ratings for PDL BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.